Requesting The Department Of Health To Convene A Medicinal Psilocybin And Psilocin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Psilocin And Develop A Long-term Strategic Plan To Ensure The Availability Of Medicinal Psilocybin And Psilocin Or Psilocybin-based And Psilocin-based Products That Are Safe, Accessible, And Affordable For Eligible Adult Patients.
Impact
The working group is tasked with comprehensively reviewing the current federal, state, and local regulations regarding the medicinal application of psilocybin and psilocin. Moreover, it will examine scientific studies and research exploring the safety and efficacy of these compounds in mental health treatments. By pursuing this initiative, Hawaii aims to improve access to alternative therapies that could address the state's mental health crisis, which is especially relevant given the growing acknowledgment of psilocybin's potential as a breakthrough therapy for severe depression as noted by the FDA.
Summary
Senate Concurrent Resolution 5 (SCR5) requests the Hawaii Department of Health to establish a Medicinal Psilocybin and Psilocin Working Group. The aim of this group is to explore the medicinal benefits and therapeutic effects of psilocybin and psilocin, two naturally occurring compounds in certain mushrooms, which have been studied for their potential efficacy in treating various mental health conditions such as depression, anxiety disorders, and psychological distress at the end of life. The resolution recognizes the pressing need for innovative solutions in the face of a shortage of mental health professionals in Hawaii.
Contention
One notable aspect of SCR5 is its focus on creating a long-term strategic plan to ensure that psilocybin and psilocin products remain safe, accessible, and affordable for eligible adult patients. This initiative may lead to complications concerning current laws and regulations surrounding psychotropic substances, as the bill necessitates the formation of guidelines for medical professionals on prescribing these compounds. As such, the resolution reveals a commitment to exploring therapeutic methods that could modify the existing legal framework around mental health treatments in Hawaii, prompting discussions on potential implications for healthcare practices and regulatory oversight in the state.
Requesting That A Task Force Be Convened To Develop A Norwegian-based Public Facility Model Designated To Ensure The Well-being And Safety Of Dementia Patients.
Requesting That A Task Force Be Convened To Develop A Norwegian-based Public Facility Model Designated To Ensure The Well-being And Safety Of Dementia Patients.
Requesting The Department Of Health's State Health Planning And Development Agency To Convene A Health Data Sharing Working Group To Accelerate And Expand The Sharing Of Real Time Health Information Among Health Care Entities And Government Agencies In The State.
Requesting The Department Of Health To Convene A Stakeholder Working Group To Make Recommendations To Enhance Meaningful Access To Health Care In The State Through The Provision Of Language Assistance Services.
Requesting The State Health Planning And Development Agency To Convene A Health Information Data Sharing Working Group To Collaborate And Establish The Framework And Standards For Future Health Information Data Sharing Legislation.
Requesting The Department Of Health's State Health Planning And Development Agency To Convene A Health Data Sharing Working Group To Accelerate And Expand The Sharing Of Real Time Health Information Among Health Care Entities And Government Agencies In The State.
Requesting The State Health Planning And Development Agency To Convene A Health Information Data Sharing Working Group To Collaborate And Establish The Framework And Standards For Future Health Information Data Sharing Legislation.
Requesting The Department Of Health To Convene A Medicinal Psilocybin And Psilocin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Psilocin And Develop A Long-term Strategic Plan To Ensure The Availability Of Medicinal Psilocybin And Psilocin Or Psilocybin-based And Psilocin-based Products That Are Safe, Accessible, And Affordable For Eligible Adult Patients.
Requesting The Department Of Health To Convene A Medicinal Psilocybin And Psilocin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Psilocin And Develop A Long-term Strategic Plan To Ensure The Availability Of Medicinal Psilocybin And Psilocin Or Psilocybin-based And Psilocin-based Products That Are Safe, Accessible, And Affordable For Eligible Adult Patients.
Controlled dangerous substances; authorizing certain research and clinical trials related to psilocybin and psilocin; requiring registration; providing certain immunities.
Requesting The Department Of Health To Convene A Medicinal Psychedelics Right-to-try Task Force To Explore The Development Of A Program For Qualifying Terminally Ill Patients.
Requesting The Department Of Health To Convene A Medicinal Psychedelics Right-to-try Task Force To Explore The Development Of A Program For Qualifying Terminally Ill Patients.